[Combination chemotherapy with cisplatin and UFT malignant tumors of the head and neck--experimental study of human nasopharyngeal carcinoma (A2L/AH) xenografted to nude mice].
Combination therapy with cis-platinum (CDDP) and UFT was examined with human nasopharyngeal carcinoma (A2L/AH) implanted in nude mice. The tumor growth of A2L/AH was inhibited in the group administrated UFT 20mg/kg, but was not in 10mg/kg group in comparison with the control group. An inhibition rate (IR) of the tumor growth was 80.2 and 21.3% respectively. The group received CDDP (5mg/kg, q7d X 3, 2mg/kg, q7d X 3 and 1 mg/kg, qd X 6) by i. p. injection, resulted in 75.2, 37.4 and 23.1% inhibitions respectively. While, the response rate in the group treated with CDDP (1 mg/kg, qd X 6) and UFT (10mg/kg) showed a synergistic effect (IR; 66.3%) which was higher than in the group administrated CDDP (2mg/kg, q7d X 3) and UFT (10mg/kg) (IR; 58.3%).
D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy*; D009368:Neoplasm Transplantation; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D005641:Tegafur; D014498:Uracil; D002945:Cisplatin